# Addiction Medicine Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Judy Garland (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML005-SYN
- Date: 2026-06-29
- Fictional facility: St. Posthumous Health Center
- Fictional author: Tobias Grünewald, MD
- Calendar frame: modern shifted

- Requested by: Margaret Ellsworth-Diaz, MD

## Reason for consultation

Long-term dependence on prescribed secobarbital and dextroamphetamine that began with pills given to her as a teenage performer, in a 33-year-old singer three months after childbirth, with depression and anxiety. Please confirm the diagnoses and advise on a safe way to withdraw the barbiturate and stop the stimulant. **S**

## History

Ms. Garland, a 33-year-old singer and actor, is seen at the request of Dr. Ellsworth-Diaz. She was given pills for energy and sleep from her early teens and has taken them ever since. For years she has taken secobarbital 200 mg at bedtime, and up to 300 mg before important days, and dextroamphetamine each morning with extra tablets on long working days. In the past week, on a single prescriber and seven-day supplies, she took 200 mg on six nights and 300 mg on one, and dextroamphetamine 10 mg each morning. She has tried to stop on her own several times and could not sleep for days. She has never had a seizure. She feels ashamed and wants to stop. She has two weeks free of performances starting next week. **S**

## Examination

| System | Finding |
|---|---|
| General | Alert; blood pressure 124/80, pulse 92 |
| Neurological | No tremor; no nystagmus; gait steady |
| Psychiatric | Engaged and candid; anxious; no signs of intoxication or withdrawal |

BP 124/80 mmHg; pulse 92 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 99% on room air; weight 46.8 kg; BMI 20.5 kg/m². All vital signs are synthetic.

## Data reviewed

Dr. Ellsworth-Diaz's intake note, safety assessment, DAST-10 6, AUDIT-C 2, PHQ-9 14, GAD-7 13 and negative Mood Disorder Questionnaire. Prescription drug monitoring program: three prescribers and two pharmacies before intake, only this clinic since. Urine drug test at intake: barbiturates and amphetamine only. Last week's results: hemoglobin 12.3 g/dL, platelets 284, sodium 139, potassium 4.1, creatinine 0.66 mg/dL, eGFR 119, glucose 82 mg/dL, AST 21, ALT 18 and GGT 24 U/L, TSH 1.9 mIU/L, ferritin 24 ng/mL. ECG: sinus rhythm, QTc 428 ms. 

## Assessment

1. **Sedative, hypnotic, or anxiolytic use disorder (barbiturate), moderate** (F13.20). Tolerance and withdrawal are not counted for a medicine taken under medical supervision. She still meets five criteria: taking more than intended, unsuccessful efforts to cut down, craving, a great deal of time spent getting prescriptions from several prescribers, and continued use despite knowing that it causes morning grogginess and worsens her low mood. That is a moderate use disorder, with physiological dependence. It began with pills given to her as a minor, and that should be said plainly to her: this is harm done to her, not a failing of hers. **S**
2. **Barbiturate withdrawal risk** (F13.20). Daily short-acting barbiturate at 200 to 300 mg for years carries a real risk of seizures and delirium if it is stopped or cut quickly. The 2025 joint benzodiazepine tapering guideline does not cover barbiturates, but its principles apply: no abrupt stop, a long-acting agent, slow reductions she agrees to, pauses when needed, and inpatient care when severe withdrawal is likely. Phenobarbital, at about 30 mg for each 100 mg of secobarbital, is the usual long-acting substitute and should be started under supervision by clinicians experienced in its use. **S**
3. **Stimulant use disorder (prescribed amphetamine), mild** (F15.10). Two criteria: extra doses beyond the prescription and unsuccessful efforts to cut down. No medicine is approved for stimulant use disorder, and there is no medical indication to continue it. Stopping can bring tiredness, sleepiness and low mood for a few weeks, so it should not be stopped during the barbiturate change; a short taper once phenobarbital is stable is reasonable. **S**
4. **Depression with anxious distress** (F32.1). Sertraline is a good choice; phenobarbital may lower its level a little, so the dose should follow her response. Psychotherapy and CBT for insomnia support the taper. Avoid benzodiazepines, Z-drugs, trazodone and sedating antihistamines for sleep, which would swap one sedative for another. **S**
5. **Naloxone and monitoring**. Naloxone reverses opioids, not barbiturates. She takes no opioid and has none in the monitoring program, and her pills all come from pharmacies, so naloxone is not needed now; it should be offered at once if an opioid is ever prescribed. Overdose risk from the barbiturate is lowered by limited supplies, locked storage, no alcohol, and the safety plan. **S**

## Recommendations

1. Admit for about four days to the addiction medicine service in the coming free week: stop secobarbital, start phenobarbital (starting near 30 mg three times daily), adjust with withdrawal scoring and seizure precautions, and discharge on the dose that keeps her free of withdrawal.
2. Then taper phenobarbital as an outpatient by no more than about 20% every two weeks, slower toward the end; pause for withdrawal symptoms, illness or a major performance; never stop abruptly.
3. Keep dextroamphetamine at 10 mg each morning with no extra doses until phenobarbital is stable, then 5 mg for two weeks and stop; check mood, sleep and appetite weekly for the first month.
4. Increase sertraline to 50 mg daily; continue psychotherapy and CBT for insomnia; no new hypnotic.
5. One prescriber, a monitoring program check before every prescription, supplies of one to two weeks, locked storage, take-back of unused pills, and urine drug testing after the change to phenobarbital and periodically, explained as part of care.
6. Medroxyprogesterone or an intrauterine device for contraception, because phenobarbital weakens pills, patches, rings and implants.
7. Naloxone is not needed now; reassess if an opioid is ever prescribed.
8. Blood count and liver tests at three to four months on phenobarbital.

## Strengths and supports

- Engagement in care and meaningful activity **S**

## Communication

Discussed with Dr. Ellsworth-Diaz, who sees her the same day. The plan was explained to Ms. Garland, who agreed and chose the dates of the admission around her work. **S**

## Follow-up

Addiction medicine team during the admission; review by video at the end of the taper or sooner if withdrawal symptoms or a return to secobarbital or a stimulant occur; Dr. Ellsworth-Diaz continues prescribing. **S**

## Guideline basis

- Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025), American Society of Addiction Medicine and nine partner organizations (J Gen Intern Med 2025;40(12):2814-2859)
- The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management (2020), American Society of Addiction Medicine (Journal of Addiction Medicine)
- The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024), American Society of Addiction Medicine and American Academy of Addiction Psychiatry (Journal of Addiction Medicine)
- Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline (2017), American Academy of Sleep Medicine (Journal of Clinical Sleep Medicine)
- U.S. Medical Eligibility Criteria for Contraceptive Use, 2024 (2024), Centers for Disease Control and Prevention (MMWR Recommendations and Reports)
- Prescription Drug Monitoring Programs (PDMPs) (2026), Centers for Disease Control and Prevention
